






 <b>TRANSMITTAL LETTER</b> <b>(General - Patent Pending)</b>				<b>Docket No.</b> <b>01160/1/US</b>		
In Re Application Of: <b>Timothy J. Hagen et al.</b>						
<b>Application No.</b> <b>10/623,228</b>	<b>Filing Date</b> <b>July 18, 2003</b>	<b>Examiner</b> <b>Laura Lynne Stockton</b>	<b>Customer No.</b> <b>26648</b>	<b>Group Art Unit</b> <b>1626</b>	<b>Confirmation No.</b> <b>2720</b>	
<b>Title: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION</b>						
<p style="text-align: center;"><u>COMMISSIONER FOR PATENTS:</u></p> <p>Transmitted herewith is:</p> <p><b>Amendment Transmittal; Response to Restriction Requirement; Itemized Postcard.</b></p> <p>in the above identified application.</p> <p><input checked="" type="checkbox"/> No additional fee is required.</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <b>19-1025</b> as described below.</p> <p><input type="checkbox"/> Charge the amount of _____</p> <p><input type="checkbox"/> Credit any overpayment.</p> <p><input checked="" type="checkbox"/> Charge any additional fee required.</p> <p><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b></p> <p> _____ Signature</p> <p><b>Patricia K. Fitzsimmons, Reg. No. 52,894</b> <b>Pharmacia Corporation of Pfizer Inc.</b> <b>P.O. Box 1027</b> <b>Chesterfield, Missouri 63006</b> <b>314.274.1490</b></p> <p>Dated: <b>November 2, 2004</b></p> <table border="1"><tr><td>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <b>November 2, 2004</b> (Date)  Signature of Person Mailing Correspondence <b>Linda K. Cooper</b> Typed or Printed Name of Person Mailing Correspondence</td></tr></table> <p>CC:</p>						I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <b>November 2, 2004</b> (Date)  Signature of Person Mailing Correspondence <b>Linda K. Cooper</b> Typed or Printed Name of Person Mailing Correspondence
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <b>November 2, 2004</b> (Date)  Signature of Person Mailing Correspondence <b>Linda K. Cooper</b> Typed or Printed Name of Person Mailing Correspondence						

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>				Docket No. <b>01160/1/US</b>	
Applicant(s): <b>Timothy J. Hagen et al.</b>					
Application No. <b>10/623,228</b>	Filing Date <b>July 18, 2003</b>	Examiner <b>Laura Lynne Stockton</b>	Customer No. <b>26648</b>	Group Art Unit <b>1626</b>	Confirmation No. <b>2720</b>
Invention: <b>SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION</b>					
					
<b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	22 -	69 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	1 -	1 =	0 x	\$88.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account <b>19-1025</b> <input type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 _____ Signature			Dated: <b>November 2, 2004</b>		
<b>Patricia K. Fitzsimmons, Reg. No. 52,894</b> <b>Pharmacia Corporation of Pfizer Inc.</b> <b>P.O. Box 1027</b> <b>Chesterfield, Missouri 63006</b> <b>314.274.1490</b>			<div style="border: 1px solid black; padding: 5px;">           I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on            _____            November 2, 2004            (Date)              _____            Signature of Person Mailing Correspondence  <b>Linda K. Cooper</b>            _____            Typed or Printed Name of Person Mailing Correspondence         </div>		
CC:					



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Hagen et al. ) GROUP ART UNIT: 1626  
SERIAL NO.: 10/623,228 ) CONFIRMATION NO.: 2720  
EXAMINER: Stockton ) ATTORNEY DOCKET NO.: 01160/1/US  
FILED: July 18, 2003 )  
TITLE: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR  
THE TREATMENT OF INFLAMMATION

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **November 2, 2004**.

  
Linda K. Cooper

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

November 2, 2004

RESPONSE TO RESTRICTION REQUIREMENT


Sir:

In response to the Office action of October 4, 2004, and subject to the foregoing traverse, Applicants elect the invention of Group I (claims 1-13, drawn to products of Formula I wherein A is  $(CH_2)_m$  or  $(CH_2)_m-W-(CH_2)_n$  and W is  $S(O)_p$  or O), and elect the species of Example 1, 3-amino-4,5-dihydronaphtho[1,2-b]thiophene-2-carboxamide. This compound has the following structure:

01160/1/US

Amendment dated November 2, 2004

Reply to Office action dated October 4, 2004



Claims 1, 2, 8-11, and 13 read on the elected species.

Applicants traverse the requirement for restriction between Groups I, IV, and VI. With respect to these Groups, Applicants elect to follow the procedure set forth in MPEP 821.04 and "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. §103(b)", 1184 Off. Gazette 86 (1996), which permits rejoinder of method claims upon the allowance of a claim to the composition of matter.

The Applicants submit that the present invention is now in condition for allowance. Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,

Patricia K. Fitzsimmons  
Registration No. 52,849

Pharmacia Corporation  
Post Office Box 1027  
St. Louis, MO 63006  
Telephone: 314.274.1490  
Facsimile: 314.274.9095

Enclosures:

Transmittal Letter  
Amendment Transmittal Letter  
Itemized Postcard